Zacks: Analysts Expect Pharmerica Corporation (PMC) Will Post Earnings of $0.52 Per Share

Equities analysts expect Pharmerica Corporation (NYSE:PMC) to report $0.52 earnings per share for the current quarter, according to Zacks. Two analysts have provided estimates for Pharmerica Corporation’s earnings. The highest EPS estimate is $0.53 and the lowest is $0.51. Pharmerica Corporation posted earnings of $0.58 per share during the same quarter last year, which suggests a negative year over year growth rate of 10.3%. The company is scheduled to report its next earnings report on Friday, February 23rd.

On average, analysts expect that Pharmerica Corporation will report full year earnings of $1.92 per share for the current year, with EPS estimates ranging from $1.90 to $1.94. For the next fiscal year, analysts anticipate that the company will post earnings of $2.17 per share, with EPS estimates ranging from $2.07 to $2.33. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover Pharmerica Corporation.

Pharmerica Corporation (NYSE:PMC) last posted its earnings results on Thursday, November 9th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.03). Pharmerica Corporation had a return on equity of 10.94% and a net margin of 0.83%. The firm had revenue of $595.10 million for the quarter, compared to analysts’ expectations of $596.80 million.

Several equities research analysts have recently issued reports on PMC shares. Zacks Investment Research raised shares of Pharmerica Corporation from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Wednesday, September 27th. ValuEngine raised shares of Pharmerica Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday, October 31st. Credit Suisse Group lowered shares of Pharmerica Corporation from an “outperform” rating to a “neutral” rating and raised their price target for the company from $29.00 to $29.25 in a research note on Friday, August 4th. They noted that the move was a valuation call. UBS AG reaffirmed a “neutral” rating and issued a $29.25 price target (up from $26.00) on shares of Pharmerica Corporation in a research note on Thursday, August 3rd. Finally, KeyCorp lowered shares of Pharmerica Corporation to an “overweight” rating in a research note on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $30.50.

TRADEMARK VIOLATION WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://ledgergazette.com/2017/11/18/zacks-analysts-expect-pharmerica-corporation-pmc-will-post-earnings-of-0-52-per-share.html.

Institutional investors have recently modified their holdings of the stock. Shell Asset Management Co. purchased a new position in Pharmerica Corporation in the 3rd quarter valued at about $1,946,000. Chicago Equity Partners LLC purchased a new position in Pharmerica Corporation in the 2nd quarter valued at about $2,061,000. Victory Capital Management Inc. lifted its stake in Pharmerica Corporation by 40.1% in the 2nd quarter. Victory Capital Management Inc. now owns 1,294,142 shares of the company’s stock valued at $33,971,000 after buying an additional 370,266 shares in the last quarter. California Public Employees Retirement System lifted its stake in Pharmerica Corporation by 13.8% in the 2nd quarter. California Public Employees Retirement System now owns 92,400 shares of the company’s stock valued at $2,426,000 after buying an additional 11,200 shares in the last quarter. Finally, Peregrine Capital Management LLC lifted its stake in Pharmerica Corporation by 2.0% in the 2nd quarter. Peregrine Capital Management LLC now owns 430,934 shares of the company’s stock valued at $11,312,000 after buying an additional 8,615 shares in the last quarter. 86.49% of the stock is currently owned by hedge funds and other institutional investors.

Pharmerica Corporation (NYSE:PMC) remained flat at $$29.15 during mid-day trading on Friday. The stock had a trading volume of 267,428 shares, compared to its average volume of 257,149. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.79 and a current ratio of 2.58. Pharmerica Corporation has a 12-month low of $22.00 and a 12-month high of $29.50. The firm has a market capitalization of $907.15, a PE ratio of 15.08, a price-to-earnings-growth ratio of 1.27 and a beta of 0.81.

Pharmerica Corporation Company Profile

Get a free copy of the Zacks research report on Pharmerica Corporation (PMC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pharmerica Corporation (NYSE:PMC)

Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply